New Year and Chrismas Offer
Clinical Trial Imaging Market

Clinical Trial Imaging Market Size, Share & Segment By Product and Service Type (Services, Software), By Modality Type (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-ray, Echocardiography), By Therapeutic area Type (Oncology, Infectious Diseases, Neurology, CVS, Endocrinology, Immunological Disorder), By End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturer, Contract Research Organizations, Academic and Government Research Institutes), and by Regions | Global Market Forecast 2022-2028

Report Id: SNS/HC/1761 | June 2022 | Region: Global | 125 Pages

Report Scope & Overview:

The Clinical Trial Imaging Market Size was valued at USD 851.03 million in 2021, and expected to reach USD 1535.8 million by 2028, and grow at a CAGR of 8.8% over the forecast period 2022-2028.

A clinical trial is an important part of the process of developing a pharmacological treatment. Clinical preliminary imaging advances has supported the decrease of medication preliminary expenses. Clinical imaging is a significant piece of the clinical advancement of new life science drugs. The visual quality extensively affects the compound's general presentation. A wide range of sicknesses can be recognized and analyzed utilizing clinical preliminary imaging. The technology aids in the analysis of human physiology, allowing for the development of disease prevention measures.

Clinical Trial Imaging Market

MARKET DYNAMICS:

DRIVERS

  • R&D budgets should be increased.

  • The pharmaceutical and biotechnology industries are seeing rapid growth.

  • CROs are becoming more prevalent.

RESTRAINTS

  • Imaging systems are expensive to implement.

OPPORTUNITIES

  • Countries that are developing

  • New imaging modalities, molecular probes, contrast agents, and radiopharmaceuticals are all being developed.

CHALLENGES

  • Clinical studies are expensive.

IMPACT OF COVID-19

The advancement of the COVID-19 pandemic has adjusted how clinical treatment is conveyed all over the planet. The COVID-19 pandemic has had a substantial impact on the clinical trial imaging business, with unfavorable changes in rules and recommendations, the closure of manufacturing facilities owing to lockdowns inventory network disturbances, and clinical preliminary enrollment gives all having an adverse consequence. Furthermore, due to lockdowns, the supply of clinical trial imaging goods to end customers has been restricted due to constrained operations in most businesses, insufficient funding for research and academic institutes, and difficulty in providing essential/post-sales services. Furthermore, this is a service-intensive sector, and due to constraints imposed to curb the spread of COVID-19, providing services has become challenging.

As a result of the pandemic forcing the temporary closure of various research centers around the world, several current experiments were put on hold.

Despite the difficult circumstances, industries are gradually recovering, and supply and distribution lines have reopened. While the number of studies for diseases like HIV and tuberculosis declined, focus shifted to COVID-19 diagnostics and therapies, increasing the demand for clinical trial imaging.

By Product and Service Type

Services and software make up the clinical trial imaging market. Because of increased R&D spending and growth in the pharmaceutical and biotechnology industries, the services category accounted for the highest proportion of the clinical trial imaging market in 2020.

By Modality Type

Contingent upon the methodology, the clinical trial imaging market is partitioned into figured tomography, attractive reverberation imaging, ultrasound, positron outflow tomography, X-beam, echocardiography, and different modalities. The computed tomography category held the biggest proportion in 2021. This market is driven by factors such as an increase in the number of CROs, an increase in R&D spending, and expansion in the pharmaceutical and biotechnology industries.

By Therapeutic area Type

Oncology, infectious diseases, neurology, CVS, endocrinology, immunological condition, and other therapeutic areas are the therapeutic areas in which the clinical trial imaging market is segmented. The oncology section was the most dominant in 2021. The growth of the pharmaceutical and biotechnology industries, as well as increased R&D spending, are driving this market.

By End User

Pharmaceutical businesses, biotechnology firms, medical device manufacturers, contract research organisations, university and government research institutes, and other end users have been categorised in the clinical trial imaging market. Pharmaceutical businesses had the highest share of the clinical trial imaging market in 2020. The expansion of this market is being fueled by an increase in pharmaceutical and biotechnology businesses, an increase in the number of CROs, and an increase in R&D spending.

COMPETITIVE LANDSCAPE:

Some of the major key players of Clinical Trial Imaging Market are as follows:  Biomedical Systems Corp, Bio Telemetry, Cardiovascular Imaging Technologies, IXICO plc, Intrinsic Imaging, Med pace, Navetas Life Sciences, Pro scan Imaging, Resonance Health, and Radiant Sage LLC.

MARKET SEGMENTATION:

By Product and Service Type

  • Services

  • Software

By Modality Type

  • Computed Tomography

  • Magnetic Resonance Imaging

  • Ultrasound

  • Positron Emission Tomography

  • X-ray

  • Echocardiography

By Therapeutic area Type

  • Oncology

  • Infectious Diseases

  • Neurology

  • CVS

  • Endocrinology

  • Immunological Disorder

By End User

  • Pharmaceutical Companies

  • Biotechnology Companies

  • Medical Device Manufacturer

  • Contract Research Organizations

  • Academic and Government Research Institutes

Clinical Trial Imaging Market

REGIONAL ANALYSIS

North America, Europe, Asia Pacific, and the Rest of the World are the regions that make up the global clinical trial imaging market. During the projection period, the Asia Pacific region is expected to increase the most. The regional market is expanding due to an increase in the incidence of chronic diseases and a growing demand for better diagnostic instruments. Aside from that, the market is expected to increase because to the increasing need for specialised and high-quality healthcare facilities to improve patient lives.

REGIONAL COVERAGE:

  • North America

    • USA

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • The Netherlands

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • south Korea

    • China

    • India

    • Australia

    • Rest of Asia-Pacific

  • The Middle East & Africa

    • Israel

    • UAE

    • South Africa

    • Rest of Middle East & Africa

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

 

Clinical Trial Imaging Market Report Scope:
Report Attributes Details
Market Size in 2021 US$ 851.03 Million
Market Size by 2028 US$ 1535.8 Million
CAGR CAGR of 8.8% From 2022 to 2028
Base Year 2021
Forecast Period 2022-2028
Historical Data 2017-2020
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Product and Service Type (Services, Software)
• By Modality Type (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-ray, Echocardiography)
• By Therapeutic area Type (Oncology, Infectious Diseases, Neurology, CVS, Endocrinology, Immunological Disorder)
• By End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturer, Contract Research Organizations, Academic and Government Research Institutes)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Clinical Trial Imaging Market are as follows:  Biomedical Systems Corp, Bio Telemetry, Cardiovascular Imaging Technologies, IXICO plc, Intrinsic Imaging, Med pace, Navetas Life Sciences, Pro scan Imaging, Resonance Health, and Radiant Sage LLC.
DRIVERS • R&D budgets should be increased.
• The pharmaceutical and biotechnology industries are seeing rapid growth.
• CROs are becoming more prevalent.
RESTRAINTS • Imaging systems are expensive to implement.


Frequently Asked Questions (FAQ) :

Asia Pacific region is expected to increase the most.

Services, Software are the sub segments of Clinical Trial Imaging market.

Key drivers of the Clinical Trial Imaging Market is the pharmaceutical and biotechnology industries are seeing rapid growth, and CROs are becoming more prevalent.

A clinical trial is an important part of the process of developing a pharmacological treatment. Clinical preliminary imaging advances has supported the decrease of medication preliminary expenses. Clinical imaging is a significant piece of the clinical advancement of new life science drugs.

Clinical Trial Imaging Market Size was valued at USD 851.03 million in 2021, and expected to reach USD 1535.8 million by 2028.


Table of Contents

 

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

 

2. Research Methodology

 

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

 

4. Impact Analysis

4.1 COVID 19 Impact Analysis

4.2 Impact of Ukraine ware

 

5. Value Chain Analysis

 

6. Porter’s 5 forces model

 

7.  PEST Analysis

  

8. Clinical Trial Imaging Market Segmentation, By Product and Service Type

8.1 Services

8.2 Software

 

9. Clinical Trial Imaging Market Segmentation, By Modality Type

9.1 Computed Tomography

9.2 Magnetic Resonance Imaging

9.3 Ultrasound

9.4 Positron Emission Tomography

9.5 X-ray

9.6 Echocardiography

 

10. Clinical Trial Imaging Market Segmentation, By Therapeutic area Type

10.1 Oncology

10.2 Infectious Diseases

10.3 Neurology

10.4 CVS

10.5 Endocrinology

10.6 Immunological Disorder

 

11. Clinical Trial Imaging Market Segmentation, By End User

11.1 Pharmaceutical Companies

11.2 Biotechnology Companies

11.3 Medical Device Manufacturer

11.4 Contract Research Organizations

11.5 Academic and Government Research Institutes

 

12. Regional Analysis

12.1 Introduction

12.2 North America

12.2.1 USA

12.2.2 Canada

12.2.3 Mexico

12.3 Europe

12.3.1 Germany

12.3.2 UK

12.3.3 France

12.3.4 Italy

12.3.5 Spain

12.3.6 The Netherlands

12.3.7 Rest of Europe

12.4 Asia-Pacific

12.4.1 Japan

12.4.2 South Korea

12.4.3 China

12.4.4 India

12.4.5 Australia

12.4.6 Rest of Asia-Pacific

12.5 The Middle East & Africa

12.5.1 Israel

12.5.2 UAE

12.5.3 South Africa

12.5.4 Rest

12.6 Latin America

12.6.1 Brazil

12.6.2 Argentina

12.6.3 Rest of Latin America

 

13 Company Profiles

13.1 Biomedical Systems Corp

            13.1.1 Financial

13.1.2 Products/ Services Offered

13.1.3 SWOT Analysis

13.1.4 The SNS view

13.2 Bio Telemetry

13.3 Cardiovascular Imaging Technologies

13.4 IXICO plc

13.5 Intrinsic Imaging

13.6 Med pace

13.7 Navetas Life Sciences

13.8 Pro scan Imaging

13.9 Resonance Health

13.10 Radiant Sage LLC.

 

14 Competitive Landscape

14.1 Competitive Benchmark

14.2 Market Share analysis

14.3 Recent Developments

 

15 Conclusion

 

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.